MarkerDB 2.0: a comprehensive molecular biomarker database for 2025

Hayley Jackson(University of Alberta), Eponine Oler(University of Alberta), Claudia Torres-Calzada(University of Alberta), Ray Kruger(University of Alberta), Amandeep Singh Hira(University of Alberta), Yamilé López‐Hernández(University of Alberta), Devanshi Pandit(University of Alberta), Jiaxuan Wang(University of Alberta), Kellie Yang(University of Alberta), Omolola Fatokun(University of Alberta), Mark Berjanskii(University of Alberta), Scott MacKay(University of Alberta), Tanvir Sajed(University of Alberta), Scott Han(University of Alberta), Robyn Woudstra(University of Alberta), Gina Sykes(University of Alberta), Jenna Poelzer(University of Alberta), Aadhavya Sivakumaran(University of Alberta), Vasuk Gautam(University of Alberta), Gane Ka‐Shu Wong(University of Alberta), David S. Wishart(University of Alberta)
Nucleic Acids Research
November 13, 2024
Cited by 19Open Access
Full Text

Abstract

MarkerDB (https://markerdb.ca) has become a leading resource for comprehensive information on molecular biomarkers. Over the past 3 years, the database has evolved significantly, reflecting the dynamic landscape of biomarker research and increasing demands from its user community. This year's update, which is called MarkerDB 2.0, introduces key improvements to enhance the database's usability, consistency and the range of biomarkers covered. These improvements include (i) the addition of thousands of new biomarkers and associated health conditions, (ii) the inclusion of many new biomarker types and categories, (iii) upgraded searches and data filtering functionalities, (iv) new features for exploring and understanding biomarker panels and (v) significantly expanded and improved descriptions. These upgrades, along with numerous minor improvements in content, interface, layout and overall website performance, have greatly enhanced MarkerDB's usability and capacity to facilitate biomarker interpretation across various research domains. MarkerDB remains committed to providing a free, publicly accessible platform for consolidated information on a wide range of molecular (protein, genetic, chromosomal and chemical/small molecule) biomarkers, covering diagnostic, prognostic, risk, monitoring, safety and response-related biomarkers. We are confident that these upgrades and updates will improve MarkerDB's user friendliness, increase its utility and greatly expand its potential applications to many other areas of clinical medicine and biomedical research.


Related Papers

No related papers found

Powered by citation graph analysis